biotech / news / / Devdiscourse
Only 10% of overweight or obese individuals are using GLP-1 injectable and oral medications.
Eli Lilly estimates only about 50% of eligible patients may access weight-loss drugs long term.
KEY POINTS
- Currently, just 10% of overweight or obese people use GLP-1 medications.
- Statin usage rates are viewed as a likely ceiling for future weight-loss drug adoption.
- Lilly's new oral drug Foundayo faces production scaling and high price barriers to broader adoption.
COMPANIES
Summarized by Newsio from Devdiscourse. How we summarize →